Associated tags: Injection, MLSS, Safety, NYSE, Patient, Pain management, Telephone, Spine
Locations: NEW YORK, PARK AVENUE, WISCONSIN, ROSELAND, NJ, US, ORMOND BEACH, FLORIDA, NE, OMAHA, NEBRASKA, SPAIN
Johns Hopkins Hospital,
MLSS,
Anesthesia,
Risk,
Trauma,
MD,
ESI,
CPT,
ASC,
Injection,
Safety,
Spine,
Pain management,
Pain,
Physician,
Epidural steroid injection,
Nursing ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida. PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers. PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.
Key Points:
- ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.
- PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers.
- PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.
- Adoption of the technology follows a successful evaluation by Dr. Sanjay Bakshi, MD, a pain management physician and CEO of PRC Alliance Pain Relief Centers in Ormond Beach, Florida.
Growth,
MLSS,
Webcast,
Telephone,
Education,
Dental Service Organizations,
Operating cost,
Hospital,
United,
CPT,
Injection,
Pain management,
STA,
Physician Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.
Key Points:
- Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.
- For the year ended December 31, 2023, international revenue was approximately $4.1 million, a decrease of $724,000 compared to December 31, 2022.
- Gross profit for the year ended December 31, 2023, was $6.8 million versus $4.9 million for the year ended December 31, 2022.
- Operating loss for the year ended December 31, 2023, was $7.1 million versus $8.8 million for the year ended December 31, 2022.
ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments
Key Points:
- ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments
The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 222156.
- A webcast and replay of the call may be accessed at Webcast URL: https://www.webcaster4.com/Webcast/Page/2306/50281 .
- An audio replay of the call will be available through April 15, 2024, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 50281.
MLSS,
Patient,
University,
Chronic pain,
ESI,
Neck pain,
Injection,
Safety,
Spine,
Pain management,
Physician,
Epidural steroid injection,
Dentistry ROSELAND, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables to Omaha Pain Physicians , a comprehensive medical pain management center in Omaha, NE.
Key Points:
- ROSELAND, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables to Omaha Pain Physicians , a comprehensive medical pain management center in Omaha, NE.
- Omaha Pain Physicians is focused on treating patients with acute and chronic pain.
- Dr. Matthew Stottle completed 10 cases using the CompuFlo Epidural system at Omaha Pain Physicians, in which he reported 100% success.
- The evaluation included Epidural Steroid Injection (ESI) procedures within the lumbar, thoracic and cervical thoracic junction of the spine.
Retrieved on:
Wednesday, February 28, 2024
ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System® (STA) with Meridian Endo & Perio , a large endodontics, periodontics and implant dentistry practice with three offices in Wisconsin.
Key Points:
- ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System® (STA) with Meridian Endo & Perio , a large endodontics, periodontics and implant dentistry practice with three offices in Wisconsin.
- Dr. Lisa Teel, periodontist and implant surgeon with Meridian Endo and Perio, stated, “Our practice is committed to adopting the latest technologies to improve the overall patient experience.
- Upon introduction, we were struck by the ease of use, as well as the STA’s ability to put patients at ease with dental anesthesia.
- Moreover, we appreciate the ongoing educational and training support provided by Milestone Scientific.”
Arjan Haverhals, Chief Executive Officer of Milestone Scientific, commented, “This latest agreement illustrates the benefits of our new direct sales model.
Retrieved on:
Tuesday, February 20, 2024
ROSELAND, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced sales of its STA Single Tooth Anesthesia System® (STA) with Maine Dental Group , a premier group of 21 dental practices across the northeastern United States.
Key Points:
- ROSELAND, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced sales of its STA Single Tooth Anesthesia System® (STA) with Maine Dental Group , a premier group of 21 dental practices across the northeastern United States.
- We are executing our new sales strategy, which allows us to leverage a lean sales organization, while providing a cost-effective means to scale the business.
- According to the American Dental Association, approximately 23% of all dentists are now affiliated with group practices and DSOs.
- We could not be more pleased with the STA, and plan on expanding its use within our group.”
Retrieved on:
Tuesday, January 16, 2024
Patient,
Injection,
Traction,
Health,
Medicare,
UTMB,
Standard of care,
Pain management,
University,
Spine,
CPT,
FDA,
Physician,
Letter,
Epidural space,
Patient safety,
Education,
MLSS,
Pharmaceutical industry I am proud to report we are making steady progress in advancing commercialization of the CompuFlo technology.
Key Points:
- I am proud to report we are making steady progress in advancing commercialization of the CompuFlo technology.
- Several advisory sites were established across the US that implemented the CompuFlo technology in their practice.
- The medical decision by physicians to use CompuFlo demonstrates the clinical utility and benefit of the technology in patient care.
- A review and analysis of claims data shared by providers indicated that roughly one-third of claims have already received positive payor reimbursement.
Retrieved on:
Wednesday, December 13, 2023
ROSELAND, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of its previously announced underwritten public offering of 4,765,000 shares of its common stock at a public offering price of $0.63 per share (the “Offering”).
Key Points:
- ROSELAND, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of its previously announced underwritten public offering of 4,765,000 shares of its common stock at a public offering price of $0.63 per share (the “Offering”).
- Gross proceeds before deducting underwriting discounts, commissions and other Offering expenses were approximately $3.0 million.
- The Company has granted the underwriter a 45-day option to purchase up to an additional 714,750 shares of common stock, on the same terms and conditions.
- The shares of common stock were offered pursuant to a registration statement on Form S-3 (File No.
Retrieved on:
Monday, December 11, 2023
ROSELAND, N.J., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the pricing of an underwritten public offering of 4,765,000 shares of its common stock at a price of $0.63 per share (the “Offering”).
Key Points:
- ROSELAND, N.J., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the pricing of an underwritten public offering of 4,765,000 shares of its common stock at a price of $0.63 per share (the “Offering”).
- Gross proceeds before underwriting discounts and commissions and estimated Offering expenses are expected to be approximately $3.0 million.
- The Offering is expected to close on December 13, 2023, subject to customary closing conditions.
- The shares of common stock are being offered pursuant to a registration statement on Form S-3 (File No.
ROSELAND, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced an underwritten public offering of shares of its common stock (the “Offering”).
Key Points:
- ROSELAND, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced an underwritten public offering of shares of its common stock (the “Offering”).
- The Company also expects to grant to the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the Offering on the same terms and conditions.
- All of the shares of common stock are being offered by the Company.
- Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus, together with the information incorporated therein, for more complete information about Milestone Scientific and the proposed Offering.
